Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
4
80%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 34 (80.0%)

Trials by Status

not_yet_recruiting240%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_3

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

NCT07286331
recruitingphase_3

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

NCT07286266
not_yet_recruitingphase_3

Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

NCT07694427
not_yet_recruitingphase_3

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

NCT07684599
recruitingphase_1

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594

Clinical Trials (5)

Showing 5 of 5 trials
NCT07286331Phase 3

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Recruiting
NCT07286266Phase 3

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Recruiting
NCT07694427Phase 3

Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

Not Yet Recruiting
NCT07684599Phase 3

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

Not Yet Recruiting
NCT06431594Phase 1

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5